Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib in Relapsed/Refractory Thymic Malignancies
NCT00718809Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2008
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of saracatinib in thymoma, thymic carcinoma (TC), sponsored by National Cancer Institute. Started Jun 2008; status: terminated.
02
Drugs
saracatinib
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT00718809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00718809.